Hypoglycemia in diabetes: The dark side of diabetes treatment. A patient-centered review
糖尿病患者发生低血糖:糖尿病治疗的负面影响。一项以患者为中心的综述
Brianna Johnson-Rabbett
Division of Diabetes, Department of Medicine, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorCorresponding Author
Elizabeth R. Seaquist
Division of Diabetes, Department of Medicine, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota
Correspondence
Elizabeth R. Seaquist, Division of Diabetes and Endocrinology, Department of Medicine, University of Minnesota, MMC 101, 420 Delaware St SE, MMC 101, Minneapolis, MN 55455.
Email: [email protected]
Search for more papers by this authorBrianna Johnson-Rabbett
Division of Diabetes, Department of Medicine, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorCorresponding Author
Elizabeth R. Seaquist
Division of Diabetes, Department of Medicine, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota
Correspondence
Elizabeth R. Seaquist, Division of Diabetes and Endocrinology, Department of Medicine, University of Minnesota, MMC 101, 420 Delaware St SE, MMC 101, Minneapolis, MN 55455.
Email: [email protected]
Search for more papers by this authorAbstract
enHypoglycemia is a frequent occurrence in patients with diabetes who are treated with insulin and insulin secretagogues. Hypoglycemia is the limiting factor that prevents patients from achieving the glycemic control known to reduce the microvascular complications of diabetes. Recurrent episodes of hypoglycemia can lead to impaired awareness of hypoglycemia where the first symptom of a low blood sugar is unconsciousness. The fear of hypoglycemia has a significant effect on the quality of life of patients and their families. In the acute setting, hypoglycemia can kill, and clinical trials have demonstrated that a single episode of severe hypoglycemia increases the risk of subsequent mortality and cardiovascular events. Clinicians must make efforts to recognize and prevent hypoglycemia in order to prevent the adverse events associated with this event. Patient education is central to these efforts. Recent developments in glucose monitoring and drug development have provided more approaches that can be used to reduce the risk of hypoglycemia in patients with diabetes.
摘要
zh接受胰岛素与胰岛素促泌剂治疗的糖尿病患者常常会发生低血糖。目前已经很明确, 控制血糖可以减少糖尿病患者发生微血管并发症的风险, 但是低血糖却是阻碍患者达到血糖控制目标的限制性因素。反复发作的低血糖可导致患者对低血糖的感知受损, 此时低血糖的第一个症状就是意识丧失。对低血糖的恐惧对患者及其家属的生活质量都有显著的影响。在紧急环境低血糖还有可能致命, 临床试验表明, 一次严重的低血糖发作会增加随后的死亡率以及心血管事件的风险。为了防止低血糖相关不良事件的发生, 临床医生必须努力识别与预防低血糖。对患者教育是这些努力的核心。最近研制出了更多的血糖监测方法与治疗药物以减少糖尿病患者发生低血糖的风险。
REFERENCES
- 1 International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017; 40: 155-157.
- 2Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991; 40: 223-226.
- 3Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet. 1994; 344: 283-287.
- 4Elliott L, Fidler C, Ditchfield A, Stissing T. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 2016; 7: 45-60.
- 5Miller ME, Bonds, DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. British Medical Journal. 2010; 340: b5444.
- 6Riddle, MC, Ambrosius, WT, Brillon, DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010; 33: 983-990. https://doi.org/10.2337/dc09-1278
- 7Khunti K, Alsifri S, Aronson R, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obesity & Metabolism. 2016; 18: 907-915.
- 8Foos V, Varol N, Curtis BH, et al. Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. J Med Econ. 2015; 18: 420-432.
- 9Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 2014; 174: 678-686.
- 10McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012; 35: 1897-1901.
- 11Bonds DE, Miller, ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. British Medical Journal. 2010; 340: b4909. https://doi.org/10.1136/bmj.b4909
- 12Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363: 1410-1418. https://doi.org/10.1056/NEJMoa1003795
- 13Leong A, Berkowitz SA, Triant VA, et al. Hypoglycemia in diabetes mellitus as a coronary artery disease risk factor in patients at elevated vascular risk. J Clin Endocrinol Metab. 2016; 101: 659-668.
- 14Lu CL, Shen HN, Hu SC, Wang JD, Li CY. A population-based study of all-cause mortality and cardiovascular disease in association with prior history of hypoglycemia among patients with type 1 diabetes. Diabetes Care. 2016; 39: 1571-1578.
- 15Robinson RTCE, Harris ND, Ireland RH, Lee S, Newman C, Heller SR. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes. 2003; 52: 1469-1474.
- 16GogitidzeJoy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010; 33: 1529-1535.
- 17Giménez M, Gilabert R, Monteagudo J, et al. Repeated episodes of hypoglycemia as a potential aggravating factor for preclinical atherosclerosis in subjects with type 1 diabetes. Diabetes Care. 2011; 34: 198-203.
- 18Ceriello A, Novials A, Ortega E, et al. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes. 2012; 61: 2993-2997.
- 19Saremi A, Bahn GD, Reaven PD. A link between hypoglycemia and progression of atherosclerosis in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2016; 39: 448-454.
- 20Jacobson AM, Musen G, Ryan CM, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007; 356: 1842-1852.
- 21Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009; 301: 1565-1572.
- 22Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012; 35: 787-793.
- 23Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, et al. Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care. 2009; 32: 1001-1006.
- 24Jauch-Chara K, Hallschmid M, Gais S, et al. Hypoglycemia during sleep impairs consolidation of declarative memory in type 1 diabetic and healthy humans. Diabetes Care. 2007; 30: 2040-2045.
- 25Harris SB, Khunti K, Landin-Olsson M, et al. Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Prefer Adherence. 2013; 7: 925-936.
- 26Martyn-Nemeth P, Farabi SS, Mihailescu D, Nemeth J, et al. Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention - a review. J. Diabetes and Its Complications. 2016; 30: 167-177. https://doi.org/10.1016/j.jdiacomp.2015.09.003
- 27Sakane N, Kotani K, Tsuzaki K, et al. Fear of hypoglycemia and its determinants in insulin-treated patients with type 2 diabetes mellitus. J Diabetes Investig. 2015; 6: 567-570.
- 28Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabetic Med. 2008; 25: 501-504.
- 29Hopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care. 2012; 35: 1638-1642.
- 30Little SA, Leelarathna L, Walkinshaw E, et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care. 2014; 37: 2114-2122.
- 31Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes. 1994; 43: 1426-1434.
- 32Olafsdottir AF, Polonsky W, Bolinder J, et al. A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3). Diabetes Technol Ther. 2018; 20: 274-284.
- 33Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009; 94: 709-728.
- 34Cox D, Gonder-Frederick L, Polonsky W, Schlundt D, Julian D, Clarke W. A multicenter evaluation of blood glucose awareness training - II. Diabetes Care. 1995; 18: 523-528.
- 35Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013; 369: 224-232.
- 36Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016; 316: 1407-1408.
- 37Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017; 318: 33-44.
- 38Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017; 318: 45-56.
- 39Seaquist ER, Chow LS. Hypoglycemia in diabetes: does insulin type matter? JAMA. 2017; 318: 31-32.
- 40Melo KFS, Bahia LR, Pasinato B, et al. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019; 11: 13.